Table 1.
Pretherapeutic Clinicopathologic Patient Characteristics
| Sensitivity to first-line treatment (N=47) | Sensitivity to salvage treatment (N=22) | Refractory disease (N=10) | |||||
|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | ||
| Sex | |||||||
| Male | 32 | 68.1% | 18 | 81.8% | 8 | 80.0% | |
| Female | 15 | 31.9% | 4 | 18.2% | 2 | 20.0% | |
| Median age of on set (range)/year | 35(9-60) | 29(14-61) | 35(14-53) | ||||
| Subtype of pathology | |||||||
| ALCL ALK+ | 12 | 25.5% | 5 | 22.7% | 1 | 10.0% | |
| ALCL ALK- | 6 | 12.8% | 2 | 9.1% | 1 | 10.0% | |
| ALCL ALK unknown | 3 | 6.4% | 2 | 9.1% | 0 | 0.0% | |
| PTCL-NOS | 4 | 8.5% | 3 | 13.6% | 3 | 30.0% | |
| AITL | 10 | 21.3% | 3 | 13.6% | 1 | 10.0% | |
| NKTCL | 12 | 25.5% | 5 | 22.7% | 4 | 40.0% | |
| SPTCL-αβ | 0 | 0.0% | 1 | 4.5% | 0 | 0.0% | |
| SPTCL-γδ | 0 | 0.0% | 1 | 4.5% | 0 | 0.0% | |
| Stage | |||||||
| Stage I | 1 | 2.1% | 3 | 13.6% | 0 | 0.0% | |
| Stage II | 10 | 21.3% | 5 | 22.7% | 1 | 10.0% | |
| Stage III | 8 | 17.0% | 3 | 13.6% | 3 | 30.0% | |
| Stage IV | 28 | 59.6% | 11 | 50.0% | 6 | 60.0% | |
| B Symptom | 29 | 61.7% | 7 | 31.8% | 5 | 50.0% | |
| Extranodal sites >1 | 21 | 44.7% | 8 | 36.4% | 5 | 50.0% | |
| ECOG PS | |||||||
| 0 | 29 | 61.7% | 13 | 59.1% | 6 | 60.0% | |
| 1 | 14 | 29.8% | 9 | 40.9% | 4 | 40.0% | |
| 2 | 4 | 8.5% | 0 | 0.0% | 0 | 0.0% | |
| The data below excluded 22 cases whose LDH data before treatment could not be collected. * | |||||||
| (N=34) | (N=15) | (N=8) | |||||
| LDH elevated before treatment (LDH > 240U/L) | 18 | 52.9% | 3 | 20.0% | 5 | 62.5% | |
| aaIPI | |||||||
| 0 | 3 | 8.8% | 4 | 46.7% | 0 | 0.0% | |
| 1 | 13 | 38.2% | 9 | 60.0% | 4 | 50.0% | |
| 2 | 17 | 50.0% | 2 | 13.3% | 4 | 50.0% | |
| Age>60 | 1 | 2.9% | - | - | - | - | |
| PIT | |||||||
| 0 | 14 | 41.2% | 15 | 71.4% | 2 | 25.0% | |
| 1 | 17 | 50.0% | 6 | 28.6% | 5 | 62.5% | |
| 2 | 3 | 8.8% | 0 | 0.0% | 1 | 12.5% | |
* There were 22 patients whose LDH data before treatment were unavailable, such that aaIPI and PIT could only be calculated in the remaining 57 patients. Among the 57 patients, a total of 34 patients were sensitive to first line treatment, 15 patients were sensitive to salvage treatment, and the rest showed no response to chemotherapy before HDT/ASCT.
ALCL: Anaplastic large-cell lymphoma; ALK+: Anaplastic lymphoma kinase expressing; ALK-: without anaplastic lymphoma kinase expressing; PTCL-NOS: Peripheral T-cell lymphoma, not otherwise specified; AITL: Angioimmunoblastic T-cell lymphoma; NKTCL: extranodal natural killer/T-cell lymphoma, nasal type; SPTCL: Subcutaneous panniculitis-like T-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; LDH: Lactate dehydrogenase; β2-MG: β2-Microglobulin; ESR: Erythrocyte sedimentation rate; aaIPI: age adjusted International Prognostic Index; PIT: Prognostic Index for T-cell lymphoma.